Genelux Corporation Announces Productive Type C Meeting with FDA
SAN DIEGO, May 7, 2020 /PRNewswire/ — Genelux Corporation, a privately-held, clinical-stage immunotherapy company, today announced the outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA) held on May 6, 2020. The discussion focused on elements of the Company’s…
Comments Off on Genelux Corporation Announces Productive Type C Meeting with FDA